News
12-12-2011, 11:30 PM
Geron Corporation today announced the initiation of GRABM-B (GRN1005 Against Brain Metastases - Breast cancer), a Phase 2 clinical trial to evaluate GRN1005 in patients with brain metastases arising from breast cancer.
More... (http://www.news-medical.net/news/20111213/Geron-commences-GRN1005-Phase-2-trial-in-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20111213/Geron-commences-GRN1005-Phase-2-trial-in-breast-cancer.aspx)